Gerard Scimeca – Chairman, CASE
July 24, 2020
As a strong voice for American patients and consumers, CASE urges the Trump Administration to reconsider today’s executive order inserting an international pricing index into the United States health care system. While CASE supports efforts to make medicines and other treatments more affordable for patients, inserting government price controls tied to socialist systems abroad is a backwards approach. We cannot afford another attempt at price controls that will hurt patients and crush innovation when we need it most.
We also oppose the executive order allowing the importation of prescription drugs from other countries. This policy will expose American patients to health risks: these drugs have not been tested, and there is no system in place to ensure these drugs are safe, or even real.
We praise the move to hold middlemen in the healthcare system accountable. By requiring Pharmacy Benefit Managers to pass along savings to seniors at the accounts, we will add more transparency and free-market principles into the healthcare system.
